Compare Recursion Pharmaceuticals Inc (RXRX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Wells Fargo & Co trades at $90 (market cap $265.99B). The key difference: Wells Fargo & Co is far larger — about 143× Recursion Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays a 2.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WFC | |
|---|---|---|
Market Cap | $1.86B | $265.99B |
Sector | Health | Financials |
52-Week High | $6.79 | $96.40 |
52-Week Low | $2.84 | $73.42 |
Enterprise Value | $1.38B | — |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 12.78, net income margin of 25.97%, and recent Q2 2026 earnings beat. CEO Charlie Scharf emphasized strategic initiatives at the 2026 healthcare conference (CNBC, 2026-09-09), while the bank expands its wealth management division (Bloomberg via Yahoo Finance, 2026-08-28).
Outlook is cautiously positive with a consensus price target of $97.64, though risks include volatile cash flows and regulatory scrutiny. Investment opportunity lies in sustained profitability improvements and ROTCE targets, but investors face headwinds from interest rate sensitivity and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
